About Masimo (NASDAQ:MASI)
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin saturation; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. In addition, the company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, and handheld capnograph and capnometer devices; and O3 regional oximetry for tissue oxygen saturation measurement. Further, it provides Patient SafetyNet, a surveillance, remote monitoring, and clinician notification solution; MyView, a wireless presence-detection system; and connectivity devices. The company provides its products directly, as well as through distributors and original equipment manufacturers partners to hospitals, emergency medical service providers, physician offices, veterinarians, long term care facilities, and consumers. Masimo Corporation has a strategic partnership with NU Hospitals. The company was founded in 1989 and is headquartered in Irvine, California.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:MASI
CUSIP57479510
Phone949-297-7000
Debt
Debt-to-Equity RatioN/A
Current Ratio3.72%
Quick Ratio3.09%
Price-To-Earnings
Trailing P/E Ratio36.42
Forward P/E Ratio31.75
P/E Growth2.33
Sales & Book Value
Annual Sales$798.11 million
Price / Sales5.77
Cash Flow$3.0586 per share
Price / Cash29.17
Book Value$13.68 per share
Price / Book6.52
Profitability
EPS (Most Recent Fiscal Year)$2.45
Net Income$131.61 million
Net Margins16.49%
Return on Equity22.75%
Return on Assets17.54%
Miscellaneous
Employees1,400
Outstanding Shares51,640,000
Masimo (NASDAQ:MASI) Frequently Asked Questions
What is Masimo's stock symbol?
Masimo trades on the NASDAQ under the ticker symbol "MASI."
How were Masimo's earnings last quarter?
Masimo (NASDAQ:MASI) announced its quarterly earnings data on Tuesday, February, 27th. The medical equipment provider reported $0.72 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.61 by $0.11. The medical equipment provider had revenue of $225.20 million for the quarter, compared to analysts' expectations of $201.54 million. Masimo had a return on equity of 22.75% and a net margin of 16.49%. The firm's quarterly revenue was up 22.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.46 EPS. View Masimo's Earnings History.
When is Masimo's next earnings date?
What guidance has Masimo issued on next quarter's earnings?
Masimo updated its FY18 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of $2.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.66. The company issued revenue guidance of $836.0 million, compared to the consensus revenue estimate of $832.07 million.
What price target have analysts set for MASI?
6 brokers have issued 12-month price objectives for Masimo's stock. Their forecasts range from $91.00 to $112.00. On average, they expect Masimo's share price to reach $102.1667 in the next twelve months. View Analyst Ratings for Masimo.
Who are some of Masimo's key competitors?
Some companies that are related to Masimo include LivaNova (LIVN), CONMED (CNMD), NxStage (NXTM), AxoGen (AXGN), Natus Medical (BABY), Cutera (CUTR), Viewray (VRAY), Rockwell Medical (RMTI), Vision Sciences (CGNT), Helius Medical Technologies (HSDT), Zynex (ZYXI), Biolife Solutions (BLFS), Viveve Medical (VIVE), Second Sight Medical (EYES), Edap Tms (EDAP), IRIDEX (IRIX), BioSig Technologies (BSGM) and Soleno Therapeutics (SLNO).
Who are Masimo's key executives?
Masimo's management team includes the folowing people:
- Mr. Joseph E. Kiani, Founder, CEO & Chairman (Age 53)
- Mr. Anand Sampath, Chief Operating Officer (Age 52)
- Mr. Yongsam Lee, Exec. VP & Chief Information Officer (Age 53)
- Mr. Thomas Samuel McClenahan, Exec. VP, Gen. Counsel & Corp. Sec. (Age 45)
- Dr. Steven J. Barker M.D., Ph.D., Acting Chief Medical Officer and Director (Age 73)
Has Masimo been receiving favorable news coverage?
News coverage about MASI stock has trended somewhat positive recently, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Masimo earned a daily sentiment score of 0.09 on Accern's scale. They also gave media headlines about the medical equipment provider an impact score of 45.89 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Masimo?
Shares of MASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Masimo's stock price today?
One share of MASI stock can currently be purchased for approximately $89.22.
How big of a company is Masimo?
Masimo has a market capitalization of $4.58 billion and generates $798.11 million in revenue each year. The medical equipment provider earns $131.61 million in net income (profit) each year or $2.45 on an earnings per share basis. Masimo employs 1,400 workers across the globe.
How can I contact Masimo?
Masimo's mailing address is 52 DISCOVERY, IRVINE CA, 92618. The medical equipment provider can be reached via phone at 949-297-7000 or via email at [email protected]
MarketBeat Community Rating for Masimo (MASI)
MarketBeat's community ratings are surveys of what our community members think about Masimo and other stocks. Vote "Outperform" if you believe MASI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MASI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Masimo (NASDAQ:MASI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Masimo in the last 12 months. Their average twelve-month price target is $102.1667, suggesting that the stock has a possible upside of 14.51%. The high price target for MASI is $112.00 and the low price target for MASI is $91.00. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.83 | 2.83 | 2.57 | 2.57 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $102.1667 | $102.1667 | $97.00 | $97.00 |
| Price Target Upside: | 14.51% upside | 18.13% upside | 12.79% upside | 16.06% upside |
Masimo (NASDAQ:MASI) Consensus Price Target History
Masimo (NASDAQ:MASI) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Masimo (NASDAQ:MASI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Masimo (NASDAQ MASI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 16.60%
Institutional Ownership Percentage: 82.77%
Masimo (NASDAQ MASI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/2/2018 | Sanford Fitch | Director | Sell | 2,000 | $86.02 | $172,040.00 | 66,249 |  |
| 3/29/2018 | Jon Coleman | Insider | Sell | 29,303 | $87.50 | $2,564,012.50 | 20,504 | |
| 3/13/2018 | Yongsam Lee | EVP | Sell | 100 | $90.00 | $9,000.00 | 71,100 | |
| 2/1/2018 | Sanford Fitch | Director | Sell | 2,000 | $93.07 | $186,140.00 | 68,249 | |
| 2/1/2018 | Yongsam Lee | EVP | Sell | 10,000 | $92.95 | $929,500.00 | 79,000 | |
| 1/25/2018 | Sanford Fitch | Director | Sell | 2,000 | $90.00 | $180,000.00 | 70,249 | |
| 1/5/2018 | Yongsam Lee | EVP | Sell | 10,000 | $88.17 | $881,700.00 | 75,018 | |
| 12/4/2017 | Yongsam Lee | EVP | Sell | 18,198 | $88.85 | $1,616,892.30 | 70,800 | |
| 12/1/2017 | Yongsam Lee | EVP | Sell | 5,900 | $88.31 | $521,029.00 | 70,800 | |
| 11/9/2017 | Yongsam Lee | EVP | Sell | 13,976 | $89.43 | $1,249,873.68 | 74,000 | |
| 11/1/2017 | Steven Barker | Director | Sell | 10,000 | $90.00 | $900,000.00 | 73,249 | |
| 11/1/2017 | Yongsam Lee | EVP | Sell | 5,000 | $89.89 | $449,450.00 | 74,000 | |
| 8/17/2017 | Sanford Fitch | Director | Sell | 11,000 | $87.25 | $959,750.00 | 72,249 | |
| 7/20/2017 | Jon Coleman | Insider | Sell | 25,000 | $97.50 | $2,437,500.00 | 32,201 | |
| 7/14/2017 | Rick Fishel | Insider | Sell | 15,000 | $94.85 | $1,422,750.00 | 35,022 | |
| 7/13/2017 | Sanford Fitch | Director | Sell | 6,000 | $91.89 | $551,340.00 | 89,249 | |
| 7/11/2017 | Anand Sampath | COO | Sell | 40,000 | $92.00 | $3,680,000.00 | 20,000 | |
| 7/11/2017 | Rick Fishel | Insider | Sell | 15,000 | $92.85 | $1,392,750.00 | 35,022 | |
| 6/29/2017 | Sanford Fitch | Director | Sell | 14,000 | $92.06 | $1,288,840.00 | 90,249 | |
| 5/1/2017 | Joe E Kiani | CEO | Sell | 145,841 | $102.37 | $14,929,743.17 | 165,082 | |
| 4/28/2017 | Thomas Samuel Mcclenahan | EVP | Sell | 8,000 | $102.75 | $822,000.00 | 2,000 | |
| 4/26/2017 | Joe E Kiani | CEO | Sell | 154,159 | $99.70 | $15,369,652.30 | 219,241 | |
| 4/25/2017 | Joe E Kiani | CEO | Sell | 13,201 | $101.00 | $1,333,301.00 | 219,241 | |
| 4/25/2017 | Jon Coleman | Insider | Sell | 50,000 | $100.00 | $5,000,000.00 | 14,682 | |
| 4/25/2017 | Yongsam Lee | EVP | Sell | 10,000 | $100.00 | $1,000,000.00 | 79,000 | |
| 4/24/2017 | Joe E Kiani | CEO | Sell | 100,000 | $99.00 | $9,900,000.00 | 219,241 | |
| 4/24/2017 | Thomas Samuel Mcclenahan | EVP | Sell | 10,000 | $98.75 | $987,500.00 | 10,000 | |
| 4/20/2017 | Thomas Samuel Mcclenahan | EVP | Sell | 10,000 | $95.75 | $957,500.00 | 4,000 | |
| 4/19/2017 | Yongsam Lee | EVP | Sell | 10,000 | $95.00 | $950,000.00 | 79,000 | |
| 4/4/2017 | Raad Mark De | CFO | Sell | 48,000 | $93.25 | $4,476,000.00 | 14,660 | |
| 3/22/2017 | Sanford Fitch | Director | Sell | 3,000 | $93.23 | $279,690.00 | 80,000 | |
| 3/10/2017 | Paul Jansen | EVP | Sell | 55,611 | $94.47 | $5,253,571.17 | 10,000 | |
| 3/9/2017 | Ramshorst David J Van | Insider | Sell | 7,500 | $94.20 | $706,500.00 | 2,500 | |
| 2/23/2017 | Raad Mark De | CFO | Sell | 30,000 | $86.25 | $2,587,500.00 | 17,660 | |
| 2/17/2017 | Raad Mark De | CFO | Sell | 45,000 | $80.00 | $3,600,000.00 | 17,660 | |
| 2/16/2017 | Joe E Kiani | CEO | Sell | 300,000 | $80.04 | $24,012,000.00 | 119,241 | |
| 2/3/2017 | Jon Coleman | Insider | Sell | 6,000 | $75.00 | $450,000.00 | 13,182 | |
| 2/3/2017 | Raad Mark De | CFO | Sell | 15,000 | $75.00 | $1,125,000.00 | 17,660 | |
| 1/27/2017 | Jon Coleman | Insider | Sell | 5,800 | $72.50 | $420,500.00 | 8,707 | |
| 1/27/2017 | Raad Mark De | CFO | Sell | 15,000 | $72.50 | $1,087,500.00 | 17,660 | |
| 1/20/2017 | Jon Coleman | Insider | Sell | 200 | $72.50 | $14,500.00 | 7,282 | |
| 1/13/2017 | Yongsam Lee | EVP | Sell | 10,000 | $72.00 | $720,000.00 | 79,000 | |
| 1/10/2017 | Jon Coleman | Insider | Sell | 6,000 | $70.00 | $420,000.00 | 13,182 | |
| 1/10/2017 | Raad Mark De | CFO | Sell | 15,000 | $70.00 | $1,050,000.00 | 17,660 | |
| 1/10/2017 | Yongsam Lee | EVP | Sell | 10,000 | $70.00 | $700,000.00 | 79,000 | |
| 1/9/2017 | Paul Jansen | EVP | Sell | 17,945 | $68.88 | $1,236,051.60 | 17,945 | |
| 1/3/2017 | Ramshorst David J Van | Insider | Sell | 4,000 | $67.20 | $268,800.00 | 5,000 | |
| 12/27/2016 | Paul Jansen | EVP | Sell | 2,055 | $68.88 | $141,548.40 | 2,055 | |
| 12/21/2016 | Jon Coleman | Insider | Sell | 4,000 | $67.50 | $270,000.00 | 4,459 | |
| 12/16/2016 | Thomas Samuel Mcclenahan | EVP | Sell | 10,000 | $66.00 | $660,000.00 | 10,000 | |
| 12/8/2016 | Paul Jansen | EVP | Sell | 10,000 | $63.88 | $638,800.00 | 5,000 | |
| 12/7/2016 | Thomas Samuel Mcclenahan | EVP | Sell | 2,293 | $63.00 | $144,459.00 | 4,000 | |
| 12/6/2016 | Joe E Kiani | CEO | Sell | 52,859 | $62.03 | $3,278,843.77 | 119,241 | |
| 12/6/2016 | Thomas Samuel Mcclenahan | EVP | Sell | 4,000 | $63.00 | $252,000.00 | 4,000 | |
| 12/1/2016 | Joe E Kiani | CEO | Sell | 36,119 | $62.06 | $2,241,545.14 | 119,241 | |
| 11/29/2016 | Joe E Kiani | CEO | Sell | 104,870 | $62.27 | $6,530,254.90 | 119,241 | |
| 11/23/2016 | Joe E Kiani | CEO | Sell | 85,771 | $62.06 | $5,322,948.26 | 119,241 | |
| 11/22/2016 | Joe E Kiani | CEO | Sell | 869 | $62.00 | $53,878.00 | 119,241 | |
| 11/21/2016 | Joe E Kiani | CEO | Sell | 30,462 | $62.04 | $1,889,862.48 | 119,241 | |
| 11/18/2016 | Joe E Kiani | CEO | Sell | 20,381 | $62.02 | $1,264,029.62 | 119,241 | |
| 11/1/2016 | Anand Sampath | COO | Sell | 65,000 | $55.04 | $3,577,600.00 | 23,171 | |
| 10/31/2016 | Anand Sampath | COO | Sell | 51,345 | $55.05 | $2,826,542.25 | 23,171 | |
| 10/19/2016 | Sanford Fitch | Director | Sell | 2,000 | $59.05 | $118,100.00 | 46,000 | |
| 10/10/2016 | Joe E Kiani | CEO | Sell | 84,617 | $60.26 | $5,099,020.42 | 126,450 | |
| 10/10/2016 | Yongsam Lee | EVP | Sell | 30,000 | $60.50 | $1,815,000.00 | 93,000 | |
| 10/5/2016 | Sanford Fitch | Director | Sell | 2,000 | $59.58 | $119,160.00 | 48,000 | |
| 10/4/2016 | Joe E Kiani | CEO | Sell | 4,300 | $60.07 | $258,301.00 | 121,441 | |
| 10/3/2016 | Joe E Kiani | CEO | Sell | 2,200 | $60.00 | $132,000.00 | 121,441 | |
| 9/30/2016 | Thomas Samuel Mcclenahan | EVP | Sell | 10,000 | $59.00 | $590,000.00 | 10,000 | |
| 9/27/2016 | Joe E Kiani | CEO | Sell | 4,464 | $60.01 | $267,884.64 | 123,705 | |
| 9/22/2016 | Joe E Kiani | CEO | Sell | 49,484 | $60.18 | $2,977,947.12 | 158,911 | |
| 9/21/2016 | Sanford Fitch | Director | Sell | 2,000 | $59.41 | $118,820.00 | 50,000 | |
| 9/20/2016 | Joe E Kiani | CEO | Sell | 400 | $60.16 | $24,064.00 | 120,240 | |
| 9/19/2016 | Joe E Kiani | CEO | Sell | 999 | $60.03 | $59,969.97 | 120,240 | |
| 9/7/2016 | Joe E Kiani | CEO | Sell | 33,536 | $60.00 | $2,012,160.00 | 152,777 | |
| 9/7/2016 | Jon Coleman | Insider | Sell | 6,000 | $60.00 | $360,000.00 | 759 | |
| 9/7/2016 | Sanford Fitch | Director | Sell | 2,000 | $59.81 | $119,620.00 | | |
| 8/17/2016 | Sanford Fitch | Director | Sell | 2,000 | $58.11 | $116,220.00 | 54,000 | |
| 8/4/2016 | Jon Coleman | Insider | Sell | 22,000 | $56.82 | $1,250,040.00 | 10,459 | |
| 8/4/2016 | Paul Jansen | EVP | Sell | 10,000 | $58.88 | $588,800.00 | 10,000 | |
| 8/3/2016 | Sanford Fitch | Director | Sell | 2,000 | $52.62 | $105,240.00 | 56,000 | |
| 7/20/2016 | Rick Fishel | Insider | Sell | 22,000 | $53.85 | $1,184,700.00 | 42,022 | |
| 7/20/2016 | Sanford Fitch | Director | Sell | 3,000 | $53.48 | $160,440.00 | 58,000 | |
| 6/30/2016 | Ramshorst David J Van | CAO | Sell | 5,000 | $52.50 | $262,500.00 | 3,000 | |
| 6/7/2016 | Joe E Kiani | CEO | Sell | 65,048 | $50.00 | $3,252,400.00 | 175,818 | |
| 6/3/2016 | Joe E Kiani | CEO | Sell | 234,952 | $50.09 | $11,768,745.68 | 313,797 | |
| 6/1/2016 | Jon Coleman | Insider | Sell | 4,000 | $50.00 | $200,000.00 | 4,459 | |
| 5/31/2016 | Raad Mark De | CFO | Sell | 40,000 | $49.43 | $1,977,200.00 | 42,660 | |
| 5/25/2016 | Rick Fishel | Insider | Sell | 25,000 | $49.85 | $1,246,250.00 | 52,022 | |
| 5/5/2016 | Jon Coleman | Insider | Sell | 8,000 | $47.00 | $376,000.00 | 4,459 | |
| 4/28/2016 | Paul Jansen | EVP | Sell | 10,000 | $44.88 | $448,800.00 | 10,000 | |
| 4/27/2016 | Jon Coleman | Insider | Sell | 4,000 | $44.00 | $176,000.00 | 4,459 | |
| 3/23/2016 | Yongsam Lee | EVP | Sell | 96,000 | $39.96 | $3,836,160.00 | 133,000 | |
| 3/22/2016 | Yongsam Lee | EVP | Sell | 32,000 | $40.06 | $1,281,920.00 | 133,000 | |
| 3/21/2016 | Yongsam Lee | EVP | Sell | 32,000 | $39.83 | $1,274,560.00 | 133,000 | |
| 3/15/2016 | Raad Mark De | CFO | Sell | 40,000 | $39.00 | $1,560,000.00 | 42,660 | |
| 2/29/2016 | Raad Mark De | CFO | Sell | 40,000 | $38.11 | $1,524,400.00 | 42,660 | |
| 12/24/2015 | Jon Coleman | insider | Sell | 10,000 | $42.00 | $420,000.00 | 459 | |
| 12/9/2015 | Sanford Fitch | Director | Sell | 2,000 | $41.00 | $82,000.00 | 61,000 | |
| 11/11/2015 | Sanford Fitch | Director | Sell | 2,000 | $42.67 | $85,340.00 | 61,000 | |
| 11/6/2015 | Anand Sampath | COO | Sell | 45,000 | $42.00 | $1,890,000.00 | | |
| 11/6/2015 | Jon Coleman | insider | Sell | 10,000 | $42.38 | $423,800.00 | 459 | |
| 10/14/2015 | Sanford Fitch | Director | Sell | 2,000 | $39.29 | $78,580.00 | 61,000 | |
| 9/17/2015 | Paul Jansen | EVP | Sell | 10,000 | $42.88 | $428,800.00 | | |
| 9/9/2015 | Sanford Fitch | Director | Sell | 2,000 | $41.29 | $82,580.00 | 61,000 | |
| 8/31/2015 | Thomas Samuel Mcclenahan | EVP | Sell | 22,000 | $40.62 | $893,640.00 | | |
| 8/26/2015 | Paul Jansen | EVP | Sell | 10,000 | $40.88 | $408,800.00 | | |
| 7/22/2015 | Rick Fishel | Insider | Sell | 35,084 | $41.85 | $1,468,265.40 | | |
| 7/21/2015 | Joe E Kiani | CEO | Sell | 300,000 | $40.55 | $12,165,000.00 | | |
| 7/21/2015 | Steven Barker | Director | Sell | 20,000 | $40.00 | $800,000.00 | | |
| 7/8/2015 | Sanford Fitch | Director | Sell | 2,000 | $38.18 | $76,360.00 | | |
| 6/10/2015 | Sanford Fitch | Director | Sell | 2,000 | $36.49 | $72,980.00 | | |
| 6/4/2015 | Steven Barker | Director | Sell | 25,000 | $36.20 | $905,000.00 | | |
| 4/8/2015 | Sanford Fitch | Director | Sell | 2,000 | $34.57 | $69,140.00 | | |
| 2/18/2015 | Rick Fishel | Insider | Sell | 18,170 | $29.85 | $542,374.50 | | |
| 5/22/2013 | Robert Coleman | Director | Sell | 59,400 | $21.93 | $1,302,642.00 | | |
(Data available from 1/1/2013 forward)
Masimo (NASDAQ MASI) News Headlines
| Source: |
|
Masimo (NASDAQ:MASI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Masimo (NASDAQ:MASI) Income Statement, Balance Sheet and Cash Flow Statement
Masimo (NASDAQ MASI) Stock Chart for Friday, April, 20, 2018
Loading chart…
